Prusogliptin - CSPC ZhongQi Pharmaceutical Technology/National Health Research Institutes
Alternative Names: DBPR-108; Diabetes therapeutic - ScinoPharm/National Health Research InstitutesLatest Information Update: 25 Jun 2025
At a glance
- Originator National Health Research Institutes
- Developer CSPC ZhongQi Pharmaceutical Technology; National Health Research Institutes
- Class Amines; Antihyperglycaemics; Fluorobenzenes; Nitriles; Pyrrolidines; Small molecules
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Type 2 diabetes mellitus
Most Recent Events
- 17 Jun 2025 CSPC ZhongQi Pharmaceutical Technology plans a phase III trial for Type 2 diabetes mellitus (Combination therapy) in June 2025 (PO, Tablet) (NCT07026968)
- 28 Jan 2025 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In the elderly, In adults) in China (PO, Tablet)
- 23 Aug 2024 Discontinued - Phase-I for Type 2 diabetes mellitus (In volunteers) in Taiwan (PO, Capsule)